Filing Details

Accession Number:
0001209191-18-003485
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-12 19:56:10
Reporting Period:
2018-01-11
Accepted Time:
2018-01-12 19:56:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1604464 Atara Biotherapeutics Inc. ATRA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1205442 John Mcgrath 611 Gateway Boulevard
Suite 900
South San Francisco CA 94080
Evp & Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-01-11 3,500 $20.77 93,154 No 4 S Direct
Common Stock Acquisiton 2018-01-12 30,000 $11.00 123,154 No 4 M Direct
Common Stock Disposition 2018-01-12 3,500 $22.32 119,654 No 4 S Direct
Common Stock Disposition 2018-01-12 30,000 $25.00 89,654 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-01-12 30,000 $0.00 30,000 $11.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
10,000 2021-10-14 No 4 M Direct
Footnotes
  1. Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
  2. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $20.70 to $20.925. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.15 to $22.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $25.00 to $25.025. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  5. 1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014.